An observational study in Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma and Cardiovascular Diseases, sponsored by VASCage GmbH. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by VASCage GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Patients with chronic obstructive pulmonary disease (COPD) and severe asthma frequently present with cardiovascular comorbidities that contribute substantially to morbidity and mortality. Early identification and appropriate management of cardiovascular disease are increasingly recognized as important components of comprehensive care for patients with obstructive airway diseases.
The COINCIDE study is a prospective longitudinal observational cohort study conducted at the Department of Pulmonology, Medical University of Innsbruck. The study aims to systematically document cardiovascular comorbidities in patients with COPD and severe asthma and to evaluate their association with disease progression, therapeutic management, exacerbation rates, symptom burden, and pulmonary function over time.
Clinical, functional, laboratory, and imaging data obtained as part of routine clinical care will be collected prospectively during two study visits separated by approximately 24 months. Up to 350 adult participants will be enrolled and followed over a period of five years.
Cardiovascular comorbidities are among the major determinants of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD) and severe asthma. Despite guideline recommendations, systematic assessment and management of cardiovascular disease in these patient populations remain heterogeneous in routine clinical practice.
The primary objective of the COINCIDE study is to characterize the prevalence and spectrum of cardiovascular comorbidities in adult patients with COPD or severe asthma treated at a tertiary pulmonary outpatient clinic. Furthermore, the study aims to evaluate the relationship between cardiovascular comorbidities and clinical outcomes, including exacerbation frequency, symptom burden, pulmonary function, and treatment strategies.
This is a single-center, prospective, longitudinal observational cohort study conducted at the Department of Pulmonology, Department of Internal Medicine II, Medical University of Innsbruck, Austria. Clinical, functional, laboratory, and imaging findings obtained during routine care will be collected in a structured manner and analyzed longitudinally.
Participants will undergo study assessments at baseline and after approximately 24 months. The study is planned to enroll up to 350 adult patients and will be conducted over five years.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
This study's planned enrollment of 350 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →VASCage GmbH is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult patients (≥18 years) with a diagnosis of COPD GOLD Group B or E or severe asthma according to current GOLD and GINA recommendations. Participants are recruited from the specialized pulmonary outpatient clinic of the Department of Internal Medicine II, Medical University of Innsbruck, and receive routine clinical care. Patients are followed prospectively to assess cardiovascular comorbidities and their impact on clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive routine medical care according to local standards of care. No study-specific intervention, treatment allocation, or diagnostic procedure is performed.
Prevalence and characterization of cardiovascular comorbidities
Assessment of the prevalence, type, and distribution of cardiovascular comorbidities in patients with COPD and severe asthma based on clinical, laboratory, and imaging findings obtained during routine care.
Time frame: Baseline and 24 months
Exacerbation Frequency
Association between cardiovascular comorbidities and frequency of respiratory exacerbations.
Time frame: 24 months
Symptom Burden
Association between cardiovascular comorbidities and respiratory symptom burden as documented in routine clinical assessments.
Time frame: 24 months
Pulmonary Function
Association between cardiovascular comorbidities and pulmonary function parameters.
Time frame: Baseline and 24 months
Treatment Modifications
Assessment of changes in therapeutic management associated with the identification and characterization of cardiovascular comorbidities.
Time frame: 24 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2031, 54 months later.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 54 months is above that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
VASCage GmbH